Press Release: Sean Shrimpton – Pharmaceuticals | Biotechnology – Stanford Who’s Who Certified
Sean Shrimpton Joins the Exclusive Ranks of Stanford Who’s Who SINGAPORE, November 28, 2012 /Stanford Who’s Who / — Stanford Who’s Who proudly announces the addition of Sean Shrimpton  to the ranks of professional individuals as a result of his work in the pharmaceutical and biotechnology industry. As Vice president with Takeda Pharmaceutical Company Ltd as well as throughout his entire career, Sean has consistently demonstrated the dedication, vision, and skills required to be considered among the best. Takeda Pharmaceutical Company Ltd was founded in 1781 and incorporated in 1925. It is the largest pharmaceutical company in Japan and one of the leading research-based companies in the world. Takeda Pharmaceuticals operates through more than 151 subsidiaries spread across the globe and holds 16 equity-method affiliates. With operations in over 70 countries, the group promotes innovation in medicine as a way to provide better health to patients. Upholding strong ethical values, Takeda Pharmaceuticals continues to enjoy a reputation for excellence in their line of business. Sean Shrimpton joined Takeda Pharmaceutical Company Ltd in 2011 as Vice President. Armed with an education in Pharmacology from Kings College London, he launched his career in the pharmaceuticals industry as Commercial Director with the prestigious GlaxoSmithKline. He continued to accrue an extensive expertise in his leadership roles as Vice President of Global Marketing and Vice President of Asia Pacific with Nycomed. Sean is highly regarded as a seasoned marketing executive with over a decade of extensive expertise in the industry. His responsibilities focus on leading sales and marketing initiatives for Takeda pharmaceuticals throughout the Asia Pacific region. Use the following link to view more information on Sean Shrimpton  Browse the Stanford Who’s Who Social Media Branding website 
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.